youtu.be/CTcAE-V4etw?... Igns got great footage of the demo. No idea how deep into the game this is, but Hornets got an enormous amount of movement options available in all the footage shown. She's probably starting with a bunch of the Knights upgrades to start, honestly.
Hollow Knight: Silksong – Deep Docks Exploration + Lace Duel (4K 60FPS, No Sound)
YouTube video by IGN
youtu.be
August 30, 2025 at 4:10 PM
youtu.be/CTcAE-V4etw?... Igns got great footage of the demo. No idea how deep into the game this is, but Hornets got an enormous amount of movement options available in all the footage shown. She's probably starting with a bunch of the Knights upgrades to start, honestly.
CTCAE v6.0 vs. v5.0: Key Changes and Implementation
oncodaily.com/industry/ctc...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CTCAE
oncodaily.com/industry/ctc...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CTCAE
CTCAE v6.0 vs. v5.0: Key Changes and Implementation - OncoDaily
CTCAE v6.0 vs. v5.0: Key Changes and Implementation / cancer, CDUS, CTEP, DCP, NCI, NCORP, OncoDaily, Oncology
oncodaily.com
December 24, 2025 at 10:42 PM
CTCAE v6.0 vs. v5.0: Key Changes and Implementation
oncodaily.com/industry/ctc...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CTCAE
oncodaily.com/industry/ctc...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CTCAE
Such an important topic - so glad #SABCS24 included this in the program. More work needed to figure out how to include #PRO-cTCAE as an endpoint
Julia Maues @itsnotpink.bsky.social highlights all the ways #TheRightDoseInitiative benefits patients, physicians (shown), and payors—who pay for less sick visits and hospital stays from toxicity. #SABCS24
December 10, 2024 at 9:07 PM
Such an important topic - so glad #SABCS24 included this in the program. More work needed to figure out how to include #PRO-cTCAE as an endpoint
Honorable mention #MajorPROsASH: PROs in phase I trials
Phenomenal effort by @EthanBasch1 & @BiostatGirl on how PRO-CTCAE & CTCAE can aid in dose finding and provide a comprehensive picture of safety & tolerability. No excuse not to include PRO-CTCAE in early-phase trials. #ASH24
Phenomenal effort by @EthanBasch1 & @BiostatGirl on how PRO-CTCAE & CTCAE can aid in dose finding and provide a comprehensive picture of safety & tolerability. No excuse not to include PRO-CTCAE in early-phase trials. #ASH24
December 9, 2024 at 10:44 PM
Honorable mention #MajorPROsASH: PROs in phase I trials
Phenomenal effort by @EthanBasch1 & @BiostatGirl on how PRO-CTCAE & CTCAE can aid in dose finding and provide a comprehensive picture of safety & tolerability. No excuse not to include PRO-CTCAE in early-phase trials. #ASH24
Phenomenal effort by @EthanBasch1 & @BiostatGirl on how PRO-CTCAE & CTCAE can aid in dose finding and provide a comprehensive picture of safety & tolerability. No excuse not to include PRO-CTCAE in early-phase trials. #ASH24
Maybe CTCAE v6 will include "spontaneous combustion" so that there is finally a toxicity that might not be considered "well tolerated."
Although even then grade 2* will be overlooked.
(* Flames affecting a single limb, local intervention indicated, limiting age-appropriate instrumental ADL)
Although even then grade 2* will be overlooked.
(* Flames affecting a single limb, local intervention indicated, limiting age-appropriate instrumental ADL)
November 28, 2024 at 8:06 PM
Maybe CTCAE v6 will include "spontaneous combustion" so that there is finally a toxicity that might not be considered "well tolerated."
Although even then grade 2* will be overlooked.
(* Flames affecting a single limb, local intervention indicated, limiting age-appropriate instrumental ADL)
Although even then grade 2* will be overlooked.
(* Flames affecting a single limb, local intervention indicated, limiting age-appropriate instrumental ADL)
Someone made up the CTCAE criteria. Someone had to. Standardisation is essential for data comparison. But they don't capture the experience of living. Grade 3 amylase is an irrelevant blood test 99% of the time, whereas grade 2 fatigue or worse, grade 2 xerostomia may cause significant suffering.
November 28, 2024 at 7:12 PM
Someone made up the CTCAE criteria. Someone had to. Standardisation is essential for data comparison. But they don't capture the experience of living. Grade 3 amylase is an irrelevant blood test 99% of the time, whereas grade 2 fatigue or worse, grade 2 xerostomia may cause significant suffering.
AE classification can vary depending on sponsor, but generally they’ll follow CTCAE guidance: ctep.cancer.gov/protocoldeve...
ctep.cancer.gov
May 1, 2025 at 1:31 PM
AE classification can vary depending on sponsor, but generally they’ll follow CTCAE guidance: ctep.cancer.gov/protocoldeve...
Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social
June 3, 2025 at 3:46 PM
Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social
📢 Registration is still open for the ESTRO Gyn-SMART webinar on adverse event assessment in gynecological radiotherapy and the latest CTCAE v6.0 updates.
📅 11 June 2026 | ⏰ 16:00–17:00 CEST
💻 Online | ESTRO Hub
👉 https://bit.ly/3Pjr00h
#GynSMART #CTCAEv6 #CancerResearch #ESTROHUB
📅 11 June 2026 | ⏰ 16:00–17:00 CEST
💻 Online | ESTRO Hub
👉 https://bit.ly/3Pjr00h
#GynSMART #CTCAEv6 #CancerResearch #ESTROHUB
May 27, 2026 at 1:00 PM
📢 Registration is still open for the ESTRO Gyn-SMART webinar on adverse event assessment in gynecological radiotherapy and the latest CTCAE v6.0 updates.
📅 11 June 2026 | ⏰ 16:00–17:00 CEST
💻 Online | ESTRO Hub
👉 https://bit.ly/3Pjr00h
#GynSMART #CTCAEv6 #CancerResearch #ESTROHUB
📅 11 June 2026 | ⏰ 16:00–17:00 CEST
💻 Online | ESTRO Hub
👉 https://bit.ly/3Pjr00h
#GynSMART #CTCAEv6 #CancerResearch #ESTROHUB
How to select relevant items for monitoring? Case example of a pragmatic process for mapping immune checkpoint inhibitor #SideEffects to items from existing item libraries ( #CTCAE #EORTC #FACIT )
jpro.springeropen.com/articles/10....
#HRQL #JPRO #PatientCentered #PatientReported #ePRO
jpro.springeropen.com/articles/10....
#HRQL #JPRO #PatientCentered #PatientReported #ePRO
Mapping immune checkpoint inhibitor side effects to item libraries for use in real-time side effect monitoring systems - Journal of Patient-Reported Outcomes
Background Monitoring for the side effects of novel therapies using patient-reported outcomes (PROs) is critical for ensuring patient safety. Existing static patient-reported outcome measures may not ...
jpro.springeropen.com
March 10, 2025 at 5:32 PM
How to select relevant items for monitoring? Case example of a pragmatic process for mapping immune checkpoint inhibitor #SideEffects to items from existing item libraries ( #CTCAE #EORTC #FACIT )
jpro.springeropen.com/articles/10....
#HRQL #JPRO #PatientCentered #PatientReported #ePRO
jpro.springeropen.com/articles/10....
#HRQL #JPRO #PatientCentered #PatientReported #ePRO
📌 OncoTerm - Word of the Day! 👋
📌 OncoTerm - Günün Kelimesi! 👋
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #AdverseEvent #TRAE #CTCAE #AdversOlay #MedSky #OncSky #ClinicalTrials #Vocabulary
📌 OncoTerm - Günün Kelimesi! 👋
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #AdverseEvent #TRAE #CTCAE #AdversOlay #MedSky #OncSky #ClinicalTrials #Vocabulary
May 3, 2025 at 9:07 AM
📌 OncoTerm - Word of the Day! 👋
📌 OncoTerm - Günün Kelimesi! 👋
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #AdverseEvent #TRAE #CTCAE #AdversOlay #MedSky #OncSky #ClinicalTrials #Vocabulary
📌 OncoTerm - Günün Kelimesi! 👋
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #AdverseEvent #TRAE #CTCAE #AdversOlay #MedSky #OncSky #ClinicalTrials #Vocabulary
🚀 Quick Tip for ONCOassist Users!
Did you know?
You can access NCCN protocols, CTCAE v5, and AJCC staging in seconds with ONCOassist!
You can just simply simplify your workflow and focus on what matters most. 💡🔬
#ONCOassist #OncologyTools #Efficiency
Did you know?
You can access NCCN protocols, CTCAE v5, and AJCC staging in seconds with ONCOassist!
You can just simply simplify your workflow and focus on what matters most. 💡🔬
#ONCOassist #OncologyTools #Efficiency
November 18, 2024 at 12:49 PM
🚀 Quick Tip for ONCOassist Users!
Did you know?
You can access NCCN protocols, CTCAE v5, and AJCC staging in seconds with ONCOassist!
You can just simply simplify your workflow and focus on what matters most. 💡🔬
#ONCOassist #OncologyTools #Efficiency
Did you know?
You can access NCCN protocols, CTCAE v5, and AJCC staging in seconds with ONCOassist!
You can just simply simplify your workflow and focus on what matters most. 💡🔬
#ONCOassist #OncologyTools #Efficiency
🧰 “One of the most useful tools in oncology.”
Dr. Bryan Chan on how ONCOassist supports staging, toxicity grading, dose calculation & more in daily practice.
🎥 Watch now: youtu.be/lkKYq6I7nc8
🌐 Learn more at: oncoassist.com
#ONCOassist #BryanChan #OncologyTools #CancerCare #DigitalOncology #CTCAE
Dr. Bryan Chan on how ONCOassist supports staging, toxicity grading, dose calculation & more in daily practice.
🎥 Watch now: youtu.be/lkKYq6I7nc8
🌐 Learn more at: oncoassist.com
#ONCOassist #BryanChan #OncologyTools #CancerCare #DigitalOncology #CTCAE
May 28, 2025 at 1:22 PM
🧰 “One of the most useful tools in oncology.”
Dr. Bryan Chan on how ONCOassist supports staging, toxicity grading, dose calculation & more in daily practice.
🎥 Watch now: youtu.be/lkKYq6I7nc8
🌐 Learn more at: oncoassist.com
#ONCOassist #BryanChan #OncologyTools #CancerCare #DigitalOncology #CTCAE
Dr. Bryan Chan on how ONCOassist supports staging, toxicity grading, dose calculation & more in daily practice.
🎥 Watch now: youtu.be/lkKYq6I7nc8
🌐 Learn more at: oncoassist.com
#ONCOassist #BryanChan #OncologyTools #CancerCare #DigitalOncology #CTCAE
🧰 “ONCOassist is the Swiss Army knife of oncology apps.”
Dr. Rob Zielinski shares how he uses it for:
📊 TNM staging
💥 CTCAE toxicity grading
🧠 Prognostic scores
💊 Drug interaction checks & more
🎥 Watch now: youtu.be/SqzyMqrLUPc
🌐 Learn more at: oncoassist.com
#ONCOassist #RobZielinski
Dr. Rob Zielinski shares how he uses it for:
📊 TNM staging
💥 CTCAE toxicity grading
🧠 Prognostic scores
💊 Drug interaction checks & more
🎥 Watch now: youtu.be/SqzyMqrLUPc
🌐 Learn more at: oncoassist.com
#ONCOassist #RobZielinski
May 26, 2025 at 10:41 AM
🧰 “ONCOassist is the Swiss Army knife of oncology apps.”
Dr. Rob Zielinski shares how he uses it for:
📊 TNM staging
💥 CTCAE toxicity grading
🧠 Prognostic scores
💊 Drug interaction checks & more
🎥 Watch now: youtu.be/SqzyMqrLUPc
🌐 Learn more at: oncoassist.com
#ONCOassist #RobZielinski
Dr. Rob Zielinski shares how he uses it for:
📊 TNM staging
💥 CTCAE toxicity grading
🧠 Prognostic scores
💊 Drug interaction checks & more
🎥 Watch now: youtu.be/SqzyMqrLUPc
🌐 Learn more at: oncoassist.com
#ONCOassist #RobZielinski
NotebookLMのポッドキャスト生成機能が日本語対応したってことで、CTCAE v5.0のドキュメントを読み込ませてみた。
いやー、思った以上にすごいわ。何だか、これで良いじゃんという気になってしまうな。どーでも良いテレビのニュースバラエティより、よほど知的（にできる）なコンテンツを自作できるかも、とか。
#NotebookLM
いやー、思った以上にすごいわ。何だか、これで良いじゃんという気になってしまうな。どーでも良いテレビのニュースバラエティより、よほど知的（にできる）なコンテンツを自作できるかも、とか。
#NotebookLM
May 8, 2025 at 8:28 AM
NotebookLMのポッドキャスト生成機能が日本語対応したってことで、CTCAE v5.0のドキュメントを読み込ませてみた。
いやー、思った以上にすごいわ。何だか、これで良いじゃんという気になってしまうな。どーでも良いテレビのニュースバラエティより、よほど知的（にできる）なコンテンツを自作できるかも、とか。
#NotebookLM
いやー、思った以上にすごいわ。何だか、これで良いじゃんという気になってしまうな。どーでも良いテレビのニュースバラエティより、よほど知的（にできる）なコンテンツを自作できるかも、とか。
#NotebookLM
Part 4: Patient-Centered Trials in Practice: PRO-CTCAE, CSR Analytics, and FDA Guidance
Implementation, Tolerability Assessment, CSR Outputs, and Trial Design under FDA Guidance 4
tamai.blog/article/pati...
Implementation, Tolerability Assessment, CSR Outputs, and Trial Design under FDA Guidance 4
tamai.blog/article/pati...
September 8, 2026 at 1:03 PM
Part 4: Patient-Centered Trials in Practice: PRO-CTCAE, CSR Analytics, and FDA Guidance
Implementation, Tolerability Assessment, CSR Outputs, and Trial Design under FDA Guidance 4
tamai.blog/article/pati...
Implementation, Tolerability Assessment, CSR Outputs, and Trial Design under FDA Guidance 4
tamai.blog/article/pati...
Our article has been published!
Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort - Clinical and Translational Radiation Oncology
www.ctro.science/article/S240...
Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort - Clinical and Translational Radiation Oncology
www.ctro.science/article/S240...
Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort
Long-term prospective data on lung cancer patients treated with radiotherapy are limited,
restricting understanding of outcomes and sex-specific characteristics. The multicentre
REQUITE study provides...
www.ctro.science
September 8, 2026 at 11:28 AM
Our article has been published!
Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort - Clinical and Translational Radiation Oncology
www.ctro.science/article/S240...
Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort - Clinical and Translational Radiation Oncology
www.ctro.science/article/S240...
Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort www.sciencedirect.com/science/arti... #hvhebron #onco #oncorad [Text complet]
Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort
Long-term prospective data on lung cancer patients treated with radiotherapy are limited, restricting understanding of outcomes and sex-specific chara…
www.sciencedirect.com
August 28, 2026 at 6:56 PM
Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort www.sciencedirect.com/science/arti... #hvhebron #onco #oncorad [Text complet]
Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort www.sciencedirect.com/science/arti... #hvhebron #onco #oncorad [Text complet]
Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort
Prospectively collected long-term adverse event data with pre-radiotherapy assessment and regular follow-up reflecting ‘real world settings’ are still…
www.sciencedirect.com
July 6, 2026 at 9:34 AM
Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort www.sciencedirect.com/science/arti... #hvhebron #onco #oncorad [Text complet]
HemaTopics are HemaSphere publications focusing on 🔥 hematology topics. This week we focus on the latest HemaTopic by Scientific Editor L Merz, discussing the updated #CTCAE v6 & how the changes better reflect genetic diversity, such as the Duffy null variant 👉https://bit.ly/3LbIetU
November 12, 2025 at 10:02 AM
HemaTopics are HemaSphere publications focusing on 🔥 hematology topics. This week we focus on the latest HemaTopic by Scientific Editor L Merz, discussing the updated #CTCAE v6 & how the changes better reflect genetic diversity, such as the Duffy null variant 👉https://bit.ly/3LbIetU
Sharing our recent meta-analysis on the utility of cryotherapy in preventing peripheral neuropathy among #breastcancer patients. #oncsky #bcsm
pubmed.ncbi.nlm.nih.gov/39827229/
Sensory PN: RR = 0.19 [0.05–0.66], p = 0.009
Motor PN: RR = 0.18 [0.03–0.99], p = 0.0491
pubmed.ncbi.nlm.nih.gov/39827229/
Sensory PN: RR = 0.19 [0.05–0.66], p = 0.009
Motor PN: RR = 0.18 [0.03–0.99], p = 0.0491
A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel - PubMed
The use of cryotherapy decreased the occurrence of CTCAE grade ≥ 2 PN by 55%. Cold intolerance was the most frequently reported adverse effect associated with cryotherapy, but this adverse effect did ...
pubmed.ncbi.nlm.nih.gov
January 22, 2025 at 3:57 AM
Sharing our recent meta-analysis on the utility of cryotherapy in preventing peripheral neuropathy among #breastcancer patients. #oncsky #bcsm
pubmed.ncbi.nlm.nih.gov/39827229/
Sensory PN: RR = 0.19 [0.05–0.66], p = 0.009
Motor PN: RR = 0.18 [0.03–0.99], p = 0.0491
pubmed.ncbi.nlm.nih.gov/39827229/
Sensory PN: RR = 0.19 [0.05–0.66], p = 0.009
Motor PN: RR = 0.18 [0.03–0.99], p = 0.0491
How does #toxicity from #immunotherapy affect the real world patient?
Northern Norway we investigated #irAES in different #ICI combinations, with 40% of the patients experienced an #CTCAE grade 2 or more #irAE, leading to hospitalization or becoming chronic.
www.tandfonline.com/doi/full/10....
Northern Norway we investigated #irAES in different #ICI combinations, with 40% of the patients experienced an #CTCAE grade 2 or more #irAE, leading to hospitalization or becoming chronic.
www.tandfonline.com/doi/full/10....
Consequences of adverse events in cancer immunotherapy combinations – a comprehensive real-world analysis
Immune checkpoint inhibitors (ICIs) are pivotal in systemic anticancer therapy. The aim of the study was to investigate incidence, severity and consequences of immune-related adverse events (irAEs)...
www.tandfonline.com
December 10, 2025 at 11:10 AM
How does #toxicity from #immunotherapy affect the real world patient?
Northern Norway we investigated #irAES in different #ICI combinations, with 40% of the patients experienced an #CTCAE grade 2 or more #irAE, leading to hospitalization or becoming chronic.
www.tandfonline.com/doi/full/10....
Northern Norway we investigated #irAES in different #ICI combinations, with 40% of the patients experienced an #CTCAE grade 2 or more #irAE, leading to hospitalization or becoming chronic.
www.tandfonline.com/doi/full/10....
5 – #MajorPROsASH – 522 Lapen
Novel PRO tool for RT in CTCL (Skindex-16 + PRO-CTCAE + EORTC QLQ-C30). Improved QoL 1 month post RT & sustained thru 6 months. TSEBT w/ better QoL improvements vs focal RT. Severe fatigue during RT improved by 1 month. RT improves QoL! #lymsm #ASH25 @ash.hematology.org
Novel PRO tool for RT in CTCL (Skindex-16 + PRO-CTCAE + EORTC QLQ-C30). Improved QoL 1 month post RT & sustained thru 6 months. TSEBT w/ better QoL improvements vs focal RT. Severe fatigue during RT improved by 1 month. RT improves QoL! #lymsm #ASH25 @ash.hematology.org
December 4, 2025 at 8:16 PM
5 – #MajorPROsASH – 522 Lapen
Novel PRO tool for RT in CTCL (Skindex-16 + PRO-CTCAE + EORTC QLQ-C30). Improved QoL 1 month post RT & sustained thru 6 months. TSEBT w/ better QoL improvements vs focal RT. Severe fatigue during RT improved by 1 month. RT improves QoL! #lymsm #ASH25 @ash.hematology.org
Novel PRO tool for RT in CTCL (Skindex-16 + PRO-CTCAE + EORTC QLQ-C30). Improved QoL 1 month post RT & sustained thru 6 months. TSEBT w/ better QoL improvements vs focal RT. Severe fatigue during RT improved by 1 month. RT improves QoL! #lymsm #ASH25 @ash.hematology.org